Products
Products
Comprehensive cancer somatic panels
Tumor molecular profile analysis by Next Generation Sequencing technology is currently widely applied in clinical practice and has enabled the detection of predictive biomarkers of response to targeted treatment. In parallel with targeted therapies, immunotherapies are also evolving, revolutionizing cancer therapy, with Programmed Death-ligand 1 (PD-L1), Microsatellite...
Circulating tumor DNA panels
The GTL pan-cancer cell-free assay is part of a complete solution to detect multiple targets in tumor-derived DNA and RNA isolated from the plasma fraction of whole blood. The assay is sensitive enough to generate information from cell-free total nucleic acid (cfTNA) obtained from the plasma fraction of a single 10-mL tube of whole blood, using targeted next-generation...
Immunotherapy biomarkers test
Immune checkpoint inhibitors have revolutionized cancer therapeutic paradigm and substantially improved the survival of patients with advanced malignancies. However, a significant limitation is the wide variability in clinical response. There are some putative biomarkers that can identify individual who has a higher chance for a good response from the Immuno...
Hereditary cancer panels
The GT germline panel covers 50 genes reported to be associated with hereditary cancers in major organs, including breast and gynecologic (breast, ovarian, uterine), gastrointestinal (colorectal, gastric, pancreatic), endocrine (thyroid, paraganglioma/pheochromocytoma, parathyroid, pituitary), genitourinary (renal/urinary tract, prostate), skin (melanoma, basal cell)...
Blood-Based Screening
A More Pleasant Way to Screen for Colon Cancer With a Simple Blood Draw
Guardant Shield™ test is now FDA-approved for use in adults age 45 and older who are at average risk of colorectal cancer.
Minimal Residual Disease
Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors
Pashtoon M. Kasi, MD, MS1; Gordon Fehringer, PhD2; Hiroya Taniguchi, MD, PhD3; et., al.; JCO Precision Oncology, Volume 6, https://doi.org/10.1200/PO.21.00181
Consultation service
Medical and Scientific Consultation, and Sale/Marketing Development with a highly qualified and experienced consultant team, we provide consultation on the following issues - Interpretation of the sequencing reports, i.e. comprehensive cancer panel results, germline reports, etc. - Setting up hospital-based or online molecular tumor board...
Research services
We collaborate with several service providers to help physicians and scientists meet a wide range of research goals. Whole Genome Sequencing (WGS) can be applied in disease research as well as in population evolution studies. Target Capture Sequencing (TCS) can be effectively utilized for the in-depth analysis of exons (protein-coding regions of the genome)...
12 September 2024
Viewed 1594 times
